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Each year more than 1.2 million women become pregnant in the Sudan, of 
those 750,000 are in areas with high malaria transmission: intense perennial, 
high seasonal transmission or in areas of irrigation.   
Malaria in Africa is estimated to cause 15% of maternal anaemia; about 10,000 
maternal deaths / year and 35% of preventable low birth weight.  Best practices 
of malaria control during pregnancy include effective case management of 
malaria for all women in the reproductive age in malarious areas and using of 
insecticide treated nets (ITNs) and adopting of intermittent preventive 
treatment (IPT) with SP. The programme and the partners are targeting 60% 
coverage with these interventions as Abuja Declaration call for by the end of 
2005.  
  
4.1 Malaria in pregnancy:  
Malaria in pregnancy (MIP) is a peculiar disease in many ways:  
• The mortality and morbidity of MIP is higher than in non-pregnant women. 
The risk is even more increased in primigravidae.  
• There is evidence of maternal immuno-suppression in the second half of 
pregnancy which is caused by many factors: hormonal, placental and 
lymphocyte. The malaria infection itself has a marked immunosuppressive 
effect.   
• Reduced immunity in pregnancy leads to more relapses of malaria and more 
parasitaemia and so worsens clinical manifestations.  
• MIP is the risk to both mothers and baby /ies:  
o For mothers: in particular primigravidae and HIV positive women 
are at greater risk of malaria and therefore anaemia, svere malaria 
and death. o For infants: placental infection leads to low birth 
weight, a major risk for malaria and therefore in infant illness and 
deaths.  
• P. falciparum is the commonest and can lead to acute renal failure or cerebral 
malaria with convulsions and coma.  
• Transplacental infection to the foetus can occur.  
• The risks of MIP are severe so prompt chemotherapy for malaria is mandatory.  
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4.1.1 Clinical features of MIP:  
Atypical manifestations of malaria are common in pregnancy, particularly in the 
second half of pregnancy. The woman can present with fever with more 
paroxysms in the second half of pregnancy due to immuno-suppression. 
Anaemia is a common presentation and it could be due to: haemolysis of 
parasitized RBCs; increased demands of pregnancy; or profound haemolysis that 
may aggravate folate deficiency. Anaemia is more common and severe between 
16 -29 weeks, and pre-existing iron and folate deficiency can exacerbate it and 
vice versa. Anaemia increase the risk of perinatal mortality and maternal 
morbidity and mortality, the risk of pulmonary oedema, and the risk of 
postpartum haemorrhage is also higher.   
  
Splenomegaly may be present but variable in size; and pre-existing large spleen 
may regress in size in pregnancy.   
  
Acute pulmonary oedema is a more common and serious complication of 
MIP compared to non-pregnant population. It is more common in the second 
and third trimesters. However, it can occur immediately postpartum due to: the 
auto-transfusion of placental blood with high proportion of parasitized RBCs 
and the sudden increase in the peripheral vascular resistance after delivery.   
  
Hypoglycaemia is another complication of severe malaria and is due to:  
 increased demand of hypercatabolic state and infecting parasite,  
 hypoglycaemic response to starvation, and   
 increased response of pancreatic islets to secretary stimuli.  
Hypoglycaemia presents with symptoms similar to those of malaria. Abnormal 
behaviour, convulsions and sudden loss of consciousness are also symptos of 
cerebral malaria.   
  
Secondary infections such as urinary tract infection, pneumonias …ect are more 
common due to immuno-suppression.  
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  During pregnancy:  
o Frequency and severity are greater than in non-pregnant  
o Severe anaemia is common  
o Hyperpyrexia leading to abortion, preterm labour, intra-uterine  
foetal death and macerated still birth. o 
Hypoglycaemia  
o Transplacental infection leading to congental malaria and 
neonatal death. o Spontaneous abortion, premature birth, still 
birth, placental insufficiency and IUGR, low birth weight and 
faetal distress.  
 During labour:  
o Precipitate labour o 
Postpartum haemorrhage  
Puerperium:   
o Puerperal pyrexia o 
Difficulty in lacatation.  
 Risks to the foetus: high grade fever, placental insufficiency, 
hypoglycaemia, anaemia and other complications can adversely affect 
the foetus. Spontaneous abortions, premature birth, still birth, placental 
insufficiency and IUGR, low birth weight, and faetal distress are 
problems observed during faetal growth. Transplacental spread to the 
foetus can result in congenital malaria, which is very rare. The 
placental barrier and maternal IgG antibodies, which cross the placenta, 
may protect the foetus to some extent. Congental malaria is more 
common in the non-immune population and the incidence goes up 
during the epidemic of malaria. Faetal chloroquine and quinine levels 
are about one third of simultaneous maternal levels and this 
subtherapeutics drug level does not cure the infection in the fetus. All 
four species can cause congental malaria but it is proportionately 
common with P. malariae. The new born can present with fever, 
irritability, feeding problems, hepatosplenomegally, anaemia, and 
jaundice. The diagnosis can be confirmed by smear for malaria parasite 
from cord blood or heel prick. Febrile illness in the first week newborn 
is mostly bacterial, however think about malaria.  
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Treatment of Uncomplicated Malaria Treatment 
of falciparum Malaria:  
 ( The following guide lines are for non pregnant women. The guide lines 
for malaria in Pregnancy are described under 4.1.4 management of malaria 
in pregnancy. The information bellow is expected to add more details in the 
4.14. management of malaria in pregnancy)  
  
Falciparum malaria can present as uncomplicated (including drug resistant 
malaria) or severe (complicated) malaria. Treatment for uncomplicated (UM) 
as well as severe malaria (SM) in Sudan does not vary with regions i.e. the 
same recommended drugs applied all over the Sudan. The treatment of UM in 
Sudan has changed from mono-therapy to combination therapy.  
     
Combination therapy (CT) is the simultaneous use of two or more blood 
schizonticidal drugs with independent modes of action and different 
biochemical targets in the parasite (AS+SP / Q+AS+SP /  
Artemether+lumefantrine). There are two form of CT currently: 
Nonartemisinin and artemisinin-based combination therapy (ACT). WHO 
recommends the use of ACT.  
  
The advantages of ACT relate to the unique properties and mode of action of 
artemisinin component, which include the following:  
 Rapid substantial reduction of the parasite biomass  
 Rapid resolution of clinical symptoms  
 Effective action against multidrug-resistant P. falciparum  
 Reduction of gametocyte carriage, which may reduce transmission of 
resistant alleles   
 No parasite resistance documented as yet with the use of artemisinin and 
its derivatives  
 Few reported adverse clinical effects.  
     
2.1 Treatment for uncomplicated falciparum malaria:  
  
Treatment for uncomplicated malaria will be presented in two distinct sections:   
• Recommended malaria treatment: This is the most safe and cost- 
effective malaria treatment.  
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• Treatment not recommended: This includes the use of antimalarial 
drugs not included in the above section and adjuvant antibiotics for 
malaria treatment.  
  
2.1.1 Recommended treatment for uncomplicated malaria:  
As it is the safest and effective treatment, the national malaria control 
programme in Sudan strongly recommends the use of the following drugs as a 
1st, 2nd  and a 3rd line treatment with the dosage and regimens indicated.  
  
First-line treatment:  
The "first-line treatment" in Sudan has been changed from chloroquine alone to 
Artesunate plus Sulfadoxine- Pyrimethamine.   
  
Artesunate (AS) is a water soluble hemisuccunate derivative of 
dihydroartemisinin. It is effective against P. falciparum which resistant to all 
other operationally used antimalarial drugs. It is a potent schizontocidal drug 
but it should be administered in combination with another effective 
schizonticidal drug to prevent recrudescence and delay the selection of 
resistant strain. AS also reduces the gametocyte carriage rate. The drug is 
available in Sudan in form of tablets with two concentrations: 50 mg for 
children and 100 mg for adult. Side effects of AS are not common, transient 
rise in transaminases and transient reduction in reticulocyte count has been 
reported.  
  
Sulfadoxine- Pyrimethamine (SP) is a fixed dose combination of two antifolate 
compounds, which have schizonticidal activity against P. falciparum but less 
effective against other species. SP is available in Sudan in a form of tablets 
(500 mg Sulfadoxine +25 mg Pyrimethamine) and injection. Side effects of SP 
are mild and reversible such as gastro-intestinal disturbance, visual 
disturbance, cutaneous reaction (common), anorexia and insomnia.   
    
The total recommended dose for this combination is: □ 
AS: 4 mg / kg body weight once a day for 3 days.  
  
□ SP: 25 mg/ kg body weight Sulfadoxine +1.25 mg/ kg body weight 
Pyrimethamine as a single dose.  
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The dose and regimen of this combination should be as follow:  o 
First dose: both AS + SP simultaneously.   
           (4 mg / kg AS) + (25 mg / kg Sulfadoxine + 1.25 mg / Kg Pyrimethamine).  
  
o Second dose:  only AS  
4 mg / kg of body weight (after 24 hours from the first dose).   
  
o Third dose:  AS only  
4 mg / kg of body weight (after 24 hours from the second dose)  
  
For the dose per age group see the table (Table 1) on the cover of the booklet….  
  
Presentation:   
The combination of (AS+SP) is available in Sudan in form of tablets. For each 
age group (range of weight) a specified number of tablets were recommended, 
as an example for adult (6) tablets of artesunate 100 mg each and (3) tablets of 
sulfadoxine-pyrimethamine constitute the full dose (See Table 1).  
  
Health care providers should give advice to the caretakers (e.g. mothers) as it 
is found to increase the compliance. It worth also to spend time on drawing the 
attention of caretakers about signs of cure as well as for treatment failure, 
which is an indicator for coming back to the health facility.  
  
Treatment failure:  
  
It is expected to see patients whose condition did not improve. In such cases, 
take proper history and re-examine the patient to know exactly the cause/s of 
treatment failure (check the adequacy of AS+SP dose and regimen, other 
causes of fever, type and quality of the drug if possible………). If still there is 
doubt about malaria, check the presence of asexual form of the parasite 
(trophozoite) in his peripheral blood film. Go for the 2nd line if still it is malaria.  
  
4.1.4 Management of MIP:  
This includes: treatment of malaria, management of complications and 
management of labour.  
Gezira Journal Of Health Sciences 2004 vol.1(1)  
EDITORIAL   
  
Gezira Journal Of Health Sciences 2004  
 vol.1(1)  
  
4.1.5 Treatment of malaria:  
 Admit the patient; assess the severity of the condition by general 
examination: pallor, jaundice, blood pressure, temperature, haemoglobin 
level and parasite count.   
 SGPT, serum bilirubin, serum creatinine and blood sugar may also need to 
be assessed.   
 Monitor the maternal and faetal vital parameters 3-4 hourly and monitor 
the intake / output daily.  
 Choose the drug according to the severity of the disease / sensitivity 
pattern.   
 Avoid over / under dosing of the drugs; avoid fluid overload or dehydration 
and maintain an adequate intake of calories.   




4.1.5.1 Treatment of UM in pregnancy:  
Treatment of MIP should only be initiated after confirmation of the diagnosis 
by the presence of fever and a positive blood film if it is available. It varies 
according to the gestational age:  
In the first trimester:  
Oral quinine is safe and is the first line of treatment all throughout pregnancy.  
The dose is 10 mg salt / Kg body weight, administered 8-hourly for 7 days.  
In the second and third trimester:  
Oral quinine in the specified dose is the first line of treatment.  Or   
Oral quinine for 3 days in the standard dose followed by sulfadoxine– 
pyrimethamine in the full treatment dose.   
 Or  
A combination of artesunate tabs (AS) and SP (AS + SP)   
  
4.1.5.2 Management of severe malaria during pregnancy:  
 In the management of severe malaria in pregnancy 
especial concern must be paid to: Anaemia, 
hypoglycemia and pulmonary oedema.  
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 Quinine dihydrochloride, quinine hydrochloride or 
quinine sulphate is the first line of treatment all through 
during pregnancy. The dose is 10 mg salt / Kg body 
weight 8-hourly for 7 days. Start with IV quinine in 10% 
glucose infusion; if for some reason quinine can not be 
given by infusion, quinine dihydrochloride can be given 
in the same dosage by IM injection diluted with sterile 
normal saline to a concentration of 60 mg / ml. the dose 
should divided into two halves and injected into both 
medial upper thighs, and shift to oral as soon as 
possible. In case there is no 10% glucose concentration 
gives one bottle of 5% glucose before administration of 
Q.   
 Random blood sugar should be done before and after Q 
administration.  
 Or quinine 10 mg / Kg body weight 8 hourly for at least 
3 days (IV or IM) and shift to (AS+SP) as soon as the 
patient can take orally; this is of course in the second 
and third trimesters.  
 Or Artemether IM 3.2 mg / Kg body weight in the first 
day (divided to two doses 12 hours apart) followed by 
1.6 mg / Kg daily for the next 6 days.  
  
4.1.6 Management of complications:  
 Pulmonary oedema: careful fluid management, back rest, 
diuretics and ventilation if needed.  
 Hypoglycaemia: 25 -50 % dextrose, 50 -100 ml IV 
followed by 10% dextrose as a continuous infusion.  
Blood sugar should be monitored every 4 -6 hours.  
 Anaemia: back cell should transfused if Hb <7 gm.  
 Renal failure: it could be pre-renal due to unrecognized 
dehydration or renal due to severe parasitaemia. 
Management involves careful management, diuretics and 
dialysis if needed.   
 Septicaemic shock or algid malaria: administration of 
third generation of cephalosporins, fluid replacement or 
monitoring of vital parameters.   
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4.1.7 Management in labour:  
Falciparum malaria induces uterine contractions, resulting in premature 
labour. The frequency and intensity of the contractions is related to the degree 
of the fever. Faetal distress is the common and recognized complication. 
Lower the temperature by using cold sponging or antipyretics such as 
paracetamol. Adequate fluid management and careful monitoring in labour are 
mandatory.  
   
The table below summaries the use of antimalarial drugs for MIP and puerperium.  
Pregnancy in 
weeks  




Drugs not recommended in  
Sudan  
0 -12  Q  Q  -  Mefloquine, halofantrine, 
artimisinin - derivatives, 
primaquine, SP  
  
13 -36  Q  or (Q+ SP) 
or  (AS + SP)  
Q or ART  
  
SP  Mefloquine, halofantrine, 
primaquine  
36 –delivery  Q  Q or  
ARM  
  
-  Mefloquine, halofantrine, 
primaquine, SP  
Puerperium  AS + SP  Q Or  
ARM  
  
-  Mefloquine, halofantrine, 
primaquine  
 AS= artesunate, SP = Sulfadoxine /pyrimethamine, ARM =artemether, Q 
=quinine   
 4.1.8 Intermittent preventive treatment (IPT).  
This is a new strategy for prevention of malaria and its consequences on mothers 
and newborns. It entails giving 2 therapeutic doses of SP. The first dose of IPT 
is in the first visit after quickening (week 16- 20) and the 2nd dose is in the next 
visit at least 4 weeks apart from the first dose. If this not happened the second 
dose can be given after but should not passed week 30. IPT is recommended only 
in high transmission areas (south and some irrigated areas in Sudan). In vivax 
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area and in low to moderate transmission areas, chloroquine can be used in a 
dose of 5 mg/kg weekly till delivery.   
  
  
